A carregar...
Rosiglitazone inhibits vascular K(ATP) channels and coronary vasodilation produced by isoprenaline
BACKGROUND AND PURPOSE: Rosiglitazone is an anti-diabetic drug improving insulin sensitivity and glucose uptake in skeletal muscle and adipose tissues. However, several recent clinical trials suggest that rosiglitazone can increase the risk of cardiovascular ischaemia, although other studies failed...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3246668/ https://ncbi.nlm.nih.gov/pubmed/21671900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01539.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|